Bristol Myers Squibb's Camzyos Receives FDA Expanded Indication Approval

The U.S. Food and Drug Administration (FDA) has approved an expanded indication for Bristol Myers Squibb's Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (OHCM) in adult and pediatric patients.